Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer.

Carnevale J, Ko AH.

Future Oncol. 2016 Feb;12(4):453-64. doi: 10.2217/fon.15.333. Epub 2015 Dec 21. Review.

PMID:
26685802
2.

Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.

Chiang NJ, Chang JY, Shan YS, Chen LT.

Expert Opin Pharmacother. 2016 Jul;17(10):1413-20. doi: 10.1080/14656566.2016.1183646. Epub 2016 May 17. Review.

PMID:
27140876
3.

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT.

Br J Cancer. 2013 Aug 20;109(4):920-5. doi: 10.1038/bjc.2013.408. Epub 2013 Jul 23.

4.

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.

Ko AH.

Int J Nanomedicine. 2016 Mar 31;11:1225-35. doi: 10.2147/IJN.S88084. eCollection 2016. Review.

5.

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.

Passero FC Jr, Grapsa D, Syrigos KN, Saif MW.

Expert Rev Anticancer Ther. 2016 Jul;16(7):697-703. doi: 10.1080/14737140.2016.1192471. Epub 2016 Jun 3. Review.

PMID:
27219482
6.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group.

Lancet. 2016 Feb 6;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.

PMID:
26615328
7.

Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.

Ur Rehman SS, Lim K, Wang-Gillam A.

Expert Rev Anticancer Ther. 2016 May;16(5):485-92. doi: 10.1080/14737140.2016.1174581. Epub 2016 Apr 22. Review.

PMID:
27043737
8.

Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer.

Bien H, Mackenzie GG, Choi M.

Recent Pat Anticancer Drug Discov. 2016;11(4):376-383. Review.

PMID:
27480831
9.

Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.

Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S.

Cancer Treat Rev. 2016 Nov;50:142-147. doi: 10.1016/j.ctrv.2016.09.001. Epub 2016 Sep 9. Review.

PMID:
27676174
10.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.

Cancer Med. 2016 Apr;5(4):676-83. doi: 10.1002/cam4.635. Epub 2016 Jan 24.

11.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

12.

Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.

Garcia G, Odaimi M.

J Gastrointest Cancer. 2017 Jun;48(2):121-128. doi: 10.1007/s12029-017-9930-0. Review.

PMID:
28303435
13.

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M.

Crit Rev Oncol Hematol. 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. Review.

PMID:
28602164
15.
16.

Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.

Cinar P, Ko AH.

Chin Clin Oncol. 2017 Jun;6(3):29. doi: 10.21037/cco.2017.06.13. Review.

17.

Irinotecan (Campto) in the treatment of pancreatic cancer.

Pizzolato JF, Saltz LB.

Expert Rev Anticancer Ther. 2003 Oct;3(5):587-93. Review.

PMID:
14599083
18.

Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.

Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T.

Med Oncol. 2016 Apr;33(4):37. doi: 10.1007/s12032-016-0753-9. Epub 2016 Mar 19.

19.
20.

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.

Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU, Woo SM.

Chemotherapy. 2013;59(4):273-9. doi: 10.1159/000356158. Epub 2014 Jan 18.

PMID:
24457620

Supplemental Content

Support Center